Cathay International Holdings Ld Result of Lansen EGM (0774E)
13 July 2016 - 8:02PM
UK Regulatory
TIDMCTI
RNS Number : 0774E
Cathay International Holdings Ld
13 July 2016
Cathay International Holdings Limited
("Cathay" or the "Company")
Poll Results of Lansen Pharmaceutical Holdings Limited
Extraordinary General Meeting ("EGM") Held on 13 July 2016
Hong Kong, 13 July 2016 - Cathay International Holdings Ltd.
(LSE: CTI.L), a leading operator and investor in the growing
healthcare sector in the People's Republic of China, today
announces that its subsidiary Lansen Pharmaceutical Holdings Ltd
("Lansen") (HKEX: 503), in which the Company has a 50.56% holding,
has announced that at its EGM held today, the proposed resolutions
relating to the second tranche subscription in Haotian and the
Cross Guarantee Agreement were duly passed by its independent
shareholders.
The full text of the Lansen Announcement can be found at
http://www.hkexnews.hk/listedco/listconews/SEHK/2016/0713/LTN20160713472.pdf
and will also be made available at the Announcements & Notices
section of Lansen's homepage at
http://www.lansen.com.cn/En/Announcements&Notices.asp.
- ENDS -
For further enquiries, please contact:
Cathay International Holdings
Limited Tel: +852 2828 9289
Eric Siu (Finance Director)
Patrick Sung (Director and
Controller)
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Tel: +44 (0) 203
Neal / Lindsey Neville 709 5702
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and a leading operator and
investor in the growing healthcare sector in the People's Republic
of China (the "PRC").
The Company and its subsidiaries (collectively the "Group") aim
to leverage on growth opportunities in the strong and growing
domestic demand for high quality healthcare products in the PRC and
build its portfolio companies into market sector leaders with
competitive edge. Cathay has already demonstrated a strong track
record of identifying high-growth potential investment
opportunities in this area including: Lansen, a leading specialty
pharmaceutical company focused on rheumatology and dermatology in
the PRC; Haizi, a company engaged in the manufacture, marketing and
sale of inositol and its by-product, di-calcium phosphate;
Yangling, a company engaged in production and sales of plant
extracts for use as key active ingredients in healthcare products;
and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC,
including over 30 specialist corporate and business development
staff based at the holding company's offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment.
For more information please visit the Company's website:
www.cathay-intl.com.hk
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMGMNLFLGVZG
(END) Dow Jones Newswires
July 13, 2016 06:02 ET (10:02 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024